Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.64 |
| ▸ | DGKA | P23743 | 1/20 | 0.64 |
| ▸ | HTR2C | P28335 | 1/20 | 0.61 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.58 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.58 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.58 |
| ▸ | RAD52 | P43351 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 3/20 | 0.53 |
| ▸ | FAAH | O00519 | 1/20 | 0.53 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.53 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | PAM | P19021 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8895625 | 1.00 | NAAA (0.64) | NAAADGKAHTR2CPRSS1PRSS2 | |
| SCHEMBL7836016 | 1.00 | NAAA (0.64) | NAAADGKAHTR2CPRSS1PRSS2 | |
| SCHEMBL7837074 | 1.00 | NAAA (0.64) | NAAADGKAHTR2CPRSS1PRSS2 | |
| SCHEMBL5634633 | 1.00 | NAAA (0.64) | NAAADGKAHTR2CPRSS1PRSS2 | |
| SCHEMBL1569309 | 1.00 | NAAA (0.64) | NAAADGKAHTR2CPRSS1PRSS2 | |
| SCHEMBL7838932 | 1.00 | NAAA (0.64) | NAAADGKAHTR2CPRSS1PRSS2 | |
| SCHEMBL8896231 | 1.00 | NAAA (0.64) | NAAADGKAHTR2CPRSS1PRSS2 | |
| SCHEMBL8896172 | 1.00 | NAAA (0.64) | NAAADGKAHTR2CPRSS1PRSS2 | |
| SCHEMBL2049673 | 0.98 | NAAA (0.61) | NAAADGKAHTR2CPRSS1PRSS2 | |
| SCHEMBL126972 | 0.92 | DGKA (0.57) | NAAADGKAHTR2CPRSS1PRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239922-A1 | PHOTOCURABLE COMPOSITION | TOKYO OHKA KOGYO CO., LTD. (JP) | 2024-07-18 | — | — | US | disclosed |
| US-20240192593-A1 | PHOTOSENSITIVE COMPOSITION | TOKYO OHKA KOGYO CO., LTD. (JP) | 2024-06-13 | — | — | US | disclosed |
| US-20240191003-A1 | COMPOSITION AND PHOTOSENSITIVE COMPOSITION | TOKYO OHKA KOGYO CO., LTD. (JP) | 2024-06-13 | — | — | US | disclosed |
| CN-118108899-A | Curable resin composition, cured product, and method for producing cured product | 东京应化工业株式会社 | 2024-05-31 | — | — | CN | disclosed |
| CN-118109069-A | Resin composition, cured product, and method for producing cured product | 东京应化工业株式会社 | 2024-05-31 | — | — | CN | disclosed |
| US-11981794-B2 | Curable composition, cured product, and compound | TOKYO OHKA KOGYO CO., LTD. (JP) | 2024-05-14 | — | — | US | disclosed |
| CN-117999296-A | Composition and photosensitive composition | 东京应化工业株式会社 | 2024-05-07 | — | — | CN | disclosed |
| CN-117980346-A | Composition and photosensitive composition | 东京应化工业株式会社 | 2024-05-03 | — | — | CN | disclosed |
| CN-117980347-A | Photosensitive composition | 东京应化工业株式会社 | 2024-05-03 | — | — | CN | disclosed |
| US-20240141085-A1 | PHOTOCURABLE LIQUID COMPOSITION, CURED PRODUCT, AND METHOD FOR PRODUCING CURED PRODUCT | TOKYO OHKA KOGYO CO., LTD. (JP) | 2024-05-02 | — | — | US | disclosed |
| US-6018046-A | SELECTIVE ACTION IN INHIBITING CYCLIC GMP-PHOSPHODIESTERASE (CGMP-PDE); PHARMACEUTICALS FOR TREATING DISEASES AGAINST WHICH THE INHIBITORY ACTION IS EFFECTIVE, SUCH AS PULMONARY HYPERTENSION | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2000-01-25 | — | — | US | disclosed |
| US-5981557-A | HAVING IMPROVING EFFECTS ON THE DYSMOTILITY IN THE GASTROINTESTINAL TRACT | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 1999-11-09 | — | — | US | disclosed |
| EP-0870765-A1 | AMINOTHIAZOLE DERIVATIVES, DRUG CONTAINING THE SAME AND INTERMEDIATE IN THE PRODUCTION OF THE COMPOUNDS | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 1998-10-14 | — | — | EP | disclosed |
| US-5770108-A | HIGH SPEED RESPONSE, MOLECULAR ORIENTATION, HIGH CONTRAST, RECEPTIVITY | MITSUI TOATSU CHEMICALS, INC. (JP) | 1998-06-23 | — | — | US | disclosed |
| US-5670563-A | ORGANOTIN COMPOUND, PHOSPHORUS COMPOUND | CIBA-SPECIALTY CHEMICALS CORPORATION (US) | 1997-09-23 | — | — | US | disclosed |
| EP-0751133-A1 | Pyrimidine compound, and liquid crystal composition and liquid crystal element using the same | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1997-01-02 | — | — | EP | disclosed |
| EP-0620818-A1 | ARYL KETONES AS TESTOSTERONE 5$g(a)-REDUCTASE INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-10-26 | — | — | EP | disclosed |
| WO-1993013099-A1 | ARYL KETONES AS TESTOSTERONE 5α-REDUCTASE INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-07-08 | — | — | WO | disclosed |
| US-4229345-A | (2-Chloro-4-cyanophenyl) (4-dialkylaminophenyl)-diazine dye useful for transfer printing | BASF AKTIENGESELLSCHAFT (DE) | 1980-10-21 | — | — | US | disclosed |
| US-3935195-A | FLUORESCENT DYE | STERLING DRUG INC. (US) | 1976-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240192593-A1 | PHOTOSENSITIVE COMPOSITION | PPOX, ERCC1, ERCC5 | NAAA 1816/4885DGKA 2666/4885HTR2C 3580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.